Fresenius Med Cr SEC Filings

Fresenius Medical Care reported lower results for the three months ended March 31, 2026 as it executed major cost and portfolio programs. Revenue was €4.61 BN, down from €4.88 BN, mainly due to foreign currency and clinic divestitures, while organic growth remained positive.

Operating income fell to €286 M with a 6.2% margin, impacted by FME25+ program costs, higher personnel and IT expenses, and inflation, partly offset by favorable U.S. reimbursement effects. Net income attributable to shareholders declined to €117.5 M and EPS to €0.43, despite an ongoing €1 BN share buyback.

Cash generation improved: operating cash flow rose to €227 M and free cash flow to €40 M, while the net leverage ratio stayed within the company’s target range at 2.6x. Patient and clinic counts decreased due to portfolio optimization, but value-based care membership grew, and management highlighted persistent reimbursement and macroeconomic cost pressures.

Fresenius Medical Care reported Q1 2026 revenue of €4.61 billion, down 5.5% year on year, mainly due to currency effects, while organic growth was positive. Reported operating income fell 13.6% to €286 million, but excluding special items it rose 2.2% to €467 million, lifting the adjusted margin to 10.1%.

Net income attributable to shareholders declined 22.3% to €118 million, yet excluding special items it increased 1.7% to €251 million; adjusted basic EPS rose 8.5% to €0.91. Operating cash flow grew 39% to €227 million and free cash flow nearly doubled to €40 million.

The FME25+ transformation delivered €50 million additional quarterly savings, with related special items of €166 million in Q1 and a targeted €1.2 billion savings by end of 2027. The company completed a €1.0 billion buyback of 24.8 million shares, about 8.5% of share capital, and ended the quarter with a net leverage ratio of 2.6x. Management confirmed the 2026 outlook for broadly flat revenue and operating income growth within a mid-single-digit range at constant currency, excluding special items.

Fresenius Medical Care reported Q1 2026 revenue of €4.61 billion, down 5.5% year on year, mainly due to currency effects, while organic growth was positive. Reported operating income fell 13.6% to €286 million, but excluding special items it rose 2.2% to €467 million, lifting the adjusted margin to 10.1%.

Net income attributable to shareholders declined 22.3% to €118 million, yet excluding special items it increased 1.7% to €251 million; adjusted basic EPS rose 8.5% to €0.91. Operating cash flow grew 39% to €227 million and free cash flow nearly doubled to €40 million.

The FME25+ transformation delivered €50 million additional quarterly savings, with related special items of €166 million in Q1 and a targeted €1.2 billion savings by end of 2027. The company completed a €1.0 billion buyback of 24.8 million shares, about 8.5% of share capital, and ended the quarter with a net leverage ratio of 2.6x. Management confirmed the 2026 outlook for broadly flat revenue and operating income growth within a mid-single-digit range at constant currency, excluding special items.

Fresenius Medical Care has called its in-person Annual General Meeting for May 21, 2026 in Frankfurt and published the invitation, agenda, reports and ADR voting materials. Shareholders are asked to approve a dividend of EUR 1.49 per share on 279,288,885 dividend-entitled shares, for a proposed total dividend of about EUR 416.1 million, with EUR 2.18 billion carried forward from total distributable profit of EUR 2.60 billion for 2025. The company details an ongoing share buyback program of up to 29,288,814 shares for EUR 1 billion, of which 14,124,564 shares (around 4.81% of share capital) had been repurchased by December 31, 2025. A new five‑year authorization is proposed to repurchase and use up to 10% of share capital in treasury shares, including for cancellation, cash placements, acquisitions, and employee/share‑based compensation, with subscription rights potentially excluded within tight German-law limits. The 2025 compensation report explains that Management Board pay is 71% performance-based, driven by a short‑term bonus and a long‑term share‑linked plan, with 2025 STI target achievement ranging from about 56% to 102% depending on the executive, and a 34% overall target achievement for one long‑term 2023 allocation under the MB LTIP 2020.

Fresenius Medical Care has called its in-person Annual General Meeting for May 21, 2026 in Frankfurt and published the invitation, agenda, reports and ADR voting materials. Shareholders are asked to approve a dividend of EUR 1.49 per share on 279,288,885 dividend-entitled shares, for a proposed total dividend of about EUR 416.1 million, with EUR 2.18 billion carried forward from total distributable profit of EUR 2.60 billion for 2025. The company details an ongoing share buyback program of up to 29,288,814 shares for EUR 1 billion, of which 14,124,564 shares (around 4.81% of share capital) had been repurchased by December 31, 2025. A new five‑year authorization is proposed to repurchase and use up to 10% of share capital in treasury shares, including for cancellation, cash placements, acquisitions, and employee/share‑based compensation, with subscription rights potentially excluded within tight German-law limits. The 2025 compensation report explains that Management Board pay is 71% performance-based, driven by a short‑term bonus and a long‑term share‑linked plan, with 2025 STI target achievement ranging from about 56% to 102% depending on the executive, and a 34% overall target achievement for one long‑term 2023 allocation under the MB LTIP 2020.

Fresenius Medical Care AG filed an initial Form 3 for officer Olga Renkewitsch, indicating her status as an executive (title referenced as “See Remarks”). The provided data show no reported transactions, no derivative positions, and no specific share holdings, serving mainly as a baseline ownership disclosure.

Fresenius Medical Care, a leading global provider of dialysis products and services, has filed its Annual Report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The full report, including audited consolidated financial statements, is available on the company’s website and from the SEC.

The company treats individuals with renal diseases through a network of 3,601 dialysis clinics serving approximately 292,000 patients and supports around 4.5 million people worldwide who regularly undergo dialysis. Printed copies of the 20-F can be requested free of charge from the investor relations department.

Fresenius Medical Care, a leading global provider of dialysis products and services, has filed its Annual Report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The full report, including audited consolidated financial statements, is available on the company’s website and from the SEC.

The company treats individuals with renal diseases through a network of 3,601 dialysis clinics serving approximately 292,000 patients and supports around 4.5 million people worldwide who regularly undergo dialysis. Printed copies of the 20-F can be requested free of charge from the investor relations department.

Fresenius Medical Care AG files its annual Form 20-F, outlining its global kidney care business and risk profile. The company reports 279,288,885 ordinary shares outstanding as of the period end, and notes that Fresenius SE held 76,814,594 shares, or 26.2%, as of February 13, 2026.

The report explains a three-segment structure: Care Enablement (products and manufacturing), Care Delivery (dialysis and related services), and a new Value-Based Care segment created June 1, 2025, which manages risk-based kidney care contracts under IFRS 15 and IFRS 17. It also describes the 2023 legal conversion from a partnership limited by shares into a stock corporation and Fresenius SE’s ongoing influence via board appointment rights and trademark licensing.

Extensive risk disclosures highlight dependence on U.S. Medicare and Medicaid (Medicare and Medicaid contributed about 16% of consolidated revenue in 2025, with additional Medicaid and other government sources representing 4.7% of U.S. patient service revenue), exposure to healthcare reform and reimbursement cuts, regulatory and compliance requirements, cyber-security threats, ESG and supply-chain obligations, labor shortages, macroeconomic pressures, and €10,795 M of consolidated debt versus €14,283 M of shareholders’ equity as of December 31, 2025.

Fresenius Medical Care AG files its annual Form 20-F, outlining its global kidney care business and risk profile. The company reports 279,288,885 ordinary shares outstanding as of the period end, and notes that Fresenius SE held 76,814,594 shares, or 26.2%, as of February 13, 2026.

The report explains a three-segment structure: Care Enablement (products and manufacturing), Care Delivery (dialysis and related services), and a new Value-Based Care segment created June 1, 2025, which manages risk-based kidney care contracts under IFRS 15 and IFRS 17. It also describes the 2023 legal conversion from a partnership limited by shares into a stock corporation and Fresenius SE’s ongoing influence via board appointment rights and trademark licensing.

Extensive risk disclosures highlight dependence on U.S. Medicare and Medicaid (Medicare and Medicaid contributed about 16% of consolidated revenue in 2025, with additional Medicaid and other government sources representing 4.7% of U.S. patient service revenue), exposure to healthcare reform and reimbursement cuts, regulatory and compliance requirements, cyber-security threats, ESG and supply-chain obligations, labor shortages, macroeconomic pressures, and €10,795 M of consolidated debt versus €14,283 M of shareholders’ equity as of December 31, 2025.

Fresenius Medical Care reported a strong 2025, with revenue of €19.6 billion and operating income up 31% to €1.83 billion. On an adjusted basis, operating income rose 23% to €2.21 billion, lifting the margin to 11.3% from 9.3%.

Net income attributable to shareholders jumped 82% to €978 million, and adjusted net income rose 38% to €1.25 billion. Basic EPS increased to €3.36, or €4.28 excluding special items. Operating cash flow grew 12% to €2.68 billion and free cash flow reached €1.78 billion.

The company cut net debt to €9.2 billion and reduced its net leverage ratio to 2.5x. Management proposes a €1.49 dividend per share, about 33% of adjusted net income, and is executing a €1.0 billion share buyback while targeting further FME25+ cost savings and modest operating income growth through 2028.

Fresenius Medical Care reported a strong 2025, with revenue of €19.6 billion and operating income up 31% to €1.83 billion. On an adjusted basis, operating income rose 23% to €2.21 billion, lifting the margin to 11.3% from 9.3%.

Net income attributable to shareholders jumped 82% to €978 million, and adjusted net income rose 38% to €1.25 billion. Basic EPS increased to €3.36, or €4.28 excluding special items. Operating cash flow grew 12% to €2.68 billion and free cash flow reached €1.78 billion.

The company cut net debt to €9.2 billion and reduced its net leverage ratio to 2.5x. Management proposes a €1.49 dividend per share, about 33% of adjusted net income, and is executing a €1.0 billion share buyback while targeting further FME25+ cost savings and modest operating income growth through 2028.

Humacyte, Inc. received an updated Schedule 13D/A showing that Fresenius Medical Care Holdings, Inc. (FMCH) beneficially owns 18,312,735 shares of Humacyte common stock, representing about 9.5% of the outstanding voting shares. This percentage is based on 192,996,511 shares outstanding as of December 15, 2025. The filing explains that the stake declined from 9.9% to 9.5% solely because Humacyte’s total shares outstanding increased; FMCH and its parent Fresenius Medical Care AG (FME AG) have neither bought nor sold Humacyte shares since their initial Schedule 13D in 2021. All 18,312,735 shares are issued, outstanding, and owned directly by FMCH, while FME AG may be deemed an indirect beneficial owner through its ownership of FMCH. The amendment also notes board and management changes at FME AG and FMCH, including new roles for Dr. Charles Hugh-Jones and Joseph E. Turk following the retirement of two prior executives.

Humacyte, Inc. received an updated Schedule 13D/A showing that Fresenius Medical Care Holdings, Inc. (FMCH) beneficially owns 18,312,735 shares of Humacyte common stock, representing about 9.5% of the outstanding voting shares. This percentage is based on 192,996,511 shares outstanding as of December 15, 2025. The filing explains that the stake declined from 9.9% to 9.5% solely because Humacyte’s total shares outstanding increased; FMCH and its parent Fresenius Medical Care AG (FME AG) have neither bought nor sold Humacyte shares since their initial Schedule 13D in 2021. All 18,312,735 shares are issued, outstanding, and owned directly by FMCH, while FME AG may be deemed an indirect beneficial owner through its ownership of FMCH. The amendment also notes board and management changes at FME AG and FMCH, including new roles for Dr. Charles Hugh-Jones and Joseph E. Turk following the retirement of two prior executives.